Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

BCL2 N107_N110dup

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

BCL2/BCL2L1 ratio elevation (3)

BCL2 rearrangement + MYC amplification (2)

BCL2/MCL1 ratio elevation (2)

BCL2 elevation + IGH elevation (1)

BCL2 fusion + EZH2 mutation (1)

Chr t(11;14) + BCL2 : BCL2L1 ratio elevation (1)

Chr t(11;14) + BCL2 overexpression (1)

MYC amplification + BCL2 amplification + TNFRSF8 expression (1)

PTEN deletion + BCL2 translocation (1)

BCL2/BAX ratio elevation (0)

BCL2/BCL2L1 ratio elevation (3)

BCL2 rearrangement + MYC amplification (2)

BCL2/MCL1 ratio elevation (2)

BCL2 elevation + IGH elevation (1)

BCL2 fusion + EZH2 mutation (1)

Chr t(11;14) + BCL2 : BCL2L1 ratio elevation (1)

Chr t(11;14) + BCL2 overexpression (1)

MYC amplification + BCL2 amplification + TNFRSF8 expression (1)

PTEN deletion + BCL2 translocation (1)

BCL2/BAX ratio elevation (0)

›

BCL2 N107_N110dup

Chronic Lymphocytic Leukemia

Resistant: C3 – Early Trials

Resistant: C3 – Early Trials